Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2026
Reporting Period: Event date April 15, 2026; Signed April 17, 2026
Business Context: The Company is a biopharmaceutical entity listed on the Nasdaq Capital Market under the symbol "MBIO". This filing addresses a regulatory notice regarding stock listing compliance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice:
- Stock Price: Closed below $1.00 per share for 30 consecutive business days ending April 15, 2026.
Material Changes
The material change reported is the receipt of a notice from the Nasdaq Listing Qualifications Department indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the minimum bid price requirement. This status change has no immediate effect on the listing but initiates a compliance timeline.
Guidance, Outlook, and Risks
Compliance Timeline:
- Grace Period: 180 calendar days (until October 12, 2026) to regain compliance.
- Requirement: Achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
- Secondary Option: If the first grace period fails, the Company may be eligible for an additional 180-day period if it meets initial listing criteria and market value requirements, potentially via a reverse stock split.
- The Company intends to monitor the closing bid price and consider all available options to remedy the deficiency.
- No decision regarding specific remedial actions (such as a reverse stock split) has been made as of the filing date.
- There is no assurance the Company will successfully maintain its Nasdaq listing.
- Failure to regain compliance by October 12, 2026, could lead to delisting notices, though the Company retains the right to request a hearing before the Nasdaq Hearings Panel to stay delisting actions.
Investor Verification Checklist
- Verify the current closing bid price of MBIO stock to assess proximity to the $1.00 threshold.
- Monitor future announcements regarding the Company's decision on a reverse stock split or other capital structure changes.
- Track the Company's progress toward the October 12, 2026, compliance deadline.
- Review the Company's market value of publicly held shares to determine eligibility for a second grace period if needed.